Advanced search
Publication Cover
Expert Opinion on Drug Safety Latest Articles
Submit an article Journal homepage
0
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Quantification of Longitudinal Patient-Reported Burden of Adverse Drug Reactions Attributed to the Use of TNF-α Inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study

Benthe H. Königa Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, the NetherlandsView further author information
,
Helen R. Gosselta Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, the NetherlandsCorrespondence[email protected]
View further author information
,
Jette A. van Linta Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, the NetherlandsORCID Iconhttps://orcid.org/0000-0003-2303-6199View further author information
ORCID Icon,
Leanne J. Kossea Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, the NetherlandsView further author information
,
Bart J.F. ten Kloosterb Department of Pharmacy, Sint Maartenskliniek, Nijmegen, the Netherlands;c Department of Pharmacy, Radboudumc, Nijmegen, the NetherlandsView further author information
,
Peter M. van den Bemtd Department of Psychology, Health and Technology, University of Twente, Enschede, the NetherlandsView further author information
,
Harald E. Vonkemand Department of Psychology, Health and Technology, University of Twente, Enschede, the Netherlands;e Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente, Enschede, the NetherlandsView further author information
&
Naomi T. Jessuruna Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, the NetherlandsView further author information
 show all
Received 20 Mar 2024, Accepted 22 May 2024, Accepted author version posted online: 23 Jul 2024
Accepted author version

REFERENCES

  • Mayo Clinic MFfMEaR. Mayo Clinic Rheumatoid Arthritis 2020 [ Available from: https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648.
  • Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid arthritis. Best Practice & Research Clinical Rheumatology. 2010;24(6):733–745. doi: 10.1016/j.berh.2010.10.001
  • Norden A, Oulee A, Ivanic M, et al. The use of ultrasound to detect enthesitis as a potential guide for intervention in patients with psoriasis at risk of psoriatic arthritis: a systematic review. Int J Dermatol. 2023;62(8):973–979. doi: 10.1111/ijd.16645
  • Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013;5(1):45–54. doi: 10.1177/1759720X12468658
  • Sim BL, Daniel RS, Hong SS, et al. Pregnancy outcomes in women with rheumatoid arthritis: a systematic review and meta-analysis. J Clin Rheumatol. 2023;29(1):36–42. doi: 10.1097/RHU.0000000000001935
  • Taylor PC, Atzeni F, Balsa A, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021;10(3):509. doi: 10.3390/jcm10030509
  • Lopez-Olivo MA, Sharma G, Singh G, et al. A systematic review with meta-analysis of the effects of smoking cessation strategies in patients with rheumatoid arthritis. PLoS One. 2022;17(12):e0279065. doi: 10.1371/journal.pone.0279065
  • van Lint JA, Jessurun NT, Hebing RCF, Hoentjen F, Tas SW, Vonkeman HE, et al. Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. Drug Saf. 2020;43(9):917–25.
  • Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225–229. doi: 10.1016/j.autrev.2012.06.008
  • de Boer M, Gosselt HR, Jansen J, van Doorn MBA, Hoentjen F, Nurmohamed MT, et al. Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs). Expert Opin Drug Saf. 2023;22(3):195–202.
  • Kosse LJ, Jessurun NT, Hebing RCF, et al. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology (Oxford). 2020;59(6):1253–1261. doi: 10.1093/rheumatology/kez412
  • Davelaar JF. Patient-reported burden of adverse drug reactions attributed to the use of adalimumab and etanercept in patients with inflammatory rheumatic diseases [abstract]. Arthritis Rheumatol. 2021;73(10):0753.
  • Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software. 2015;67(1):1- 48.
  • Neerchal NK, Morel JG, Huang OX, Moluh AM, editors. A Stepwise Algorithm for Generalized Linear Mixed Models2014.
  • Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207–228. doi: 10.1080/1744666X.2019.1705785
  • Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66(10):1339–1344. doi: 10.1136/ard.2006.062760
  • Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2011(2):Cd008794.
  • Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155–163. doi: 10.1016/j.jcm.2016.02.012
  • Leon L, Gomez A, Vadillo C, et al. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol. 2018;36(1):29–35.
  • Westerink HJ, Kosse LJ, Jessurun NT, et al. Patients’ and health-care professionals’ perspectives on adverse drug reaction burden attributed to the use of biological DMARDs: a qualitative study. Expert Opin Drug Saf. 2023;22(5):417–424. doi: 10.1080/14740338.2023.2134344

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.